$MCRB News

Last published 1w ago

1w agoMCRBSeres Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
1w agoMCRBSeres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)GlobeNewswirePrevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to
1w agoMCRBSeres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation RecipientsGlobeNewswirePeer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study
3w agoMCRBSeres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026GlobeNewswireNovel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal
2mo agoMCRBSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that on September 4,
2mo agoMCRBSeres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual
3mo agoMCRBSeres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities CostsGlobeNewswireRecently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted
4mo agoMCRBResults of IST of SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) - Seres TherapeuticsEarnings Call TranscriptsThank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the series therapeutic webcast to discuss recent clinical studies results. All l
4mo agoMCRBSeres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer TreatmentGlobeNewswire80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center
4mo agoMCRBSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related EnterocolitisGlobeNewswireCAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an
5mo agoMCRBSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027GlobeNewswireAgreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones Restructured lease materially reduces ongoing annual facility
6mo agoMCRBSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual
6mo agoMCRBSeres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireClinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs
6mo agoMCRBSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel DiseaseGlobeNewswireData highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform
6mo agoMCRBSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026GlobeNewswirePharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in
7mo agoMCRBSeres Therapeutics to Present at CARB-X Investor DayGlobeNewswireCAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X
8mo agoMCRBSeres Therapeutics Corporate Updates - SERES THERAPEUTICS INCEarnings Call TranscriptsThank you for standing by. At this time, I would like to welcome everyone to the Sirius Therapeutics Corporate Update Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker
8mo agoMCRBSeres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business UpdatesGlobeNewswireAccomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory
9mo agoMCRBSeres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune DiseasesGlobeNewswireSeres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause
11mo agoMCRBSeres Therapeutics to Participate in Piper Sandler Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper
1y agoMCRBQ3 2025 Seres Therapeutics, Inc. Earnings Conference Call - SERES THERAPEUTICS INCEarnings Call TranscriptsGood day everyone and thank you for standing by. My name is RG and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Serious Therapeutics Results and Business Updates
1y agoMCRBSeres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireFollowing constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the
1y agoMCRBSeres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025GlobeNewswireCAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on
1y agoMCRBSeres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155GlobeNewswireCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical
1y agoMCRBSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell TransplantGlobeNewswireCAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase
1y agoMCRBSeres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash RunwayGlobeNewswireFollowing recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for
1y agoMCRBSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global
1y agoMCRBSeres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoMCRB SANASeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireFollowing FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat
1y agoMCRBSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025GlobeNewswireCAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on
1y agoMCRBSeres Therapeutics Announces Leadership TransitionGlobeNewswireThomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding
1y agoMCRBSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingGlobeNewswireCAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory
1y agoMCRBSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireIn line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic
1y agoMCRBSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesGlobeNewswireCAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025
1y agoMCRBSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025GlobeNewswireCAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on
1y agoMCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswireRecent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at
1y agoMCRBSeres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025GlobeNewswireCAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast
1y agoMCRBSeres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development ApproachGlobeNewswireFDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post
1y agoMCRBSeres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST SaleGlobeNewswireCAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment
1y agoMCRBSeres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate UpdatesGlobeNewswireNew SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory
1y agoMCRBSeres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan
1y agoMCRBFDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)GlobeNewswireDesignation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meeting with FDA on
1y agoMCRBSeres Therapeutics to Participate in Piper Sandler Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will
1y agoMCRBSeres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoMCRBSeres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswireSER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as
2y agoMCRBSeres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024GlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on
2y agoMCRBSeres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.AGlobeNewswireTransaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of
2y agoMCRBSeres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With NestléBusiness WireExpress Concern Regarding Report That Seres Allegedly Rebuffed an Outright Takeover Offer from Nestlé for $6.00 - $6.50 Per Share Request that the Board Immediately Provide Stockholders With the Facts Regarding Its
2y agoMCRBSeres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30GlobeNewswireCAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that its stockholders voted to approve
2y agoMCRBSeres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare